Soluble urokinase-type plasminogen activator receptor in sickle cell disease-associated chronic kidney disease

Blood Adv. 2023 May 9;7(9):1854-1857. doi: 10.1182/bloodadvances.2022008374.

Authors

Nowah Afangbedji^{1

2}, Namita Kumari¹, Sharmin Diaz¹, Fayuan Wen¹, James G Taylor^{1

3}, Sergei Nekhai^{1

3

4}, Marina Jerebtsova⁴

Affiliations

¹ Center for Sickle Cell Disease, College of Medicine, Howard University, Washington, DC.
² Department of Physiology and Biophysics, College of Medicine, Howard University, Washington, DC.
³ Department of Medicine, College of Medicine, Howard University, Washington, DC.
⁴ Department of Microbiology, College of Medicine, Howard University, Washington, DC.

No abstract available

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Humans
Receptors, Urokinase Plasminogen Activator*
Renal Insufficiency, Chronic* / complications
Signal Transduction

Substances

Receptors, Urokinase Plasminogen Activator

Grants and funding